Proceeds to Fund U.S. Commercial Expansion of Migraine Treatment Device, Nerivio® Financing Led by Philadelphia-Based New Rhein Healthcare, Selected Additional Co-Investors to Join Round at Final Closing Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other idiopathic pain conditions, closed a Series C funding round, with a first closing…
TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich Upper Nasal Space Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, announced that the U.S….
Peer-Reviewed Study Compares Treatment Results from Migraine Medications to Using Nerivio’s Remote Electrical Neuromodulation Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the publication of a study in Pain Medicine that compared adolescent response to migraine medications to their response to Remote Electrical Neuromodulation (REN) administered by Nerivio. The study found…
The First Smartphone-Controlled, Prescription Wearable Device for the Acute Treatment of Migraine, Nerivio, Wins Silver at MDEA Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that its FDA-approved acute migraine treatment wearable Nerivio® has been named a silver winner of the 2021 Medical Design Excellence Awards (MDEA) in the Digital Health…
Nerivio Patient Savings Program Allows Eligible Patients to Receive the Prescribed Wearable for Acute Treatment of Migraine for as Low as $10 Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that its FDA-authorized Nerivio® prescribed wearable for the acute treatment of migraine is now eligible for insurance coverage…
Nerivio Usage Grows Significantly Following Indication Expansion to Adolescents Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA. “We are at a crossroads for acute migraine treatment, where…
The Prescribed Wearable Device is Now indicated for Patients 12 Years Old and Above Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio® therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine…
A new partnership between CEFALY Technology and QB Medical puts wearable medical devices in the hands of health care providers and grants active military immediate relief from migraine headaches Move over lengthy approval process, a new partnership between CEFALY Technology and QB Medical, Inc. means waiting for migraine relief will be quicker, and less of a headache for active…